Top Suppliers:I want be here




147245-92-9

147245-92-9 structure
147245-92-9 structure
  • Name: Glatiramer acetate
  • Chemical Name: acetic acid,(2S)-2-amino-3-(4-hydroxyphenyl)propanoic acid,(2S)-2-aminopentanedioic acid,(2S)-2-aminopropanoic acid,(2S)-2,6-diaminohexanoic acid
  • CAS Number: 147245-92-9
  • Molecular Formula: (C9H11NO3.C6H14N2O2.C5H9NO4.C3H7NO2)x.xC2H4O2
  • Molecular Weight: 623.65000
  • Catalog: Biochemical Peptide
  • Create Date: 2018-02-16 08:00:00
  • Modify Date: 2024-01-04 13:03:55
  • Glatiramer acetate, a synthetic analogue of myelin basic protein and an immunomodulating agent, can be used for the research of multiple sclerosis. Glatiramer acetate exhibits strong and promiscuous binding to MHC molecules and consequent competition with various myelin antigens for their presentation to T cells. A further aspect of its action is potent induction of specific suppressor cells of the T helper 2 (Th2) type that migrate to the brain and lead to in situ bystander suppression[1][2][3].

Name acetic acid,(2S)-2-amino-3-(4-hydroxyphenyl)propanoic acid,(2S)-2-aminopentanedioic acid,(2S)-2-aminopropanoic acid,(2S)-2,6-diaminohexanoic acid
Synonyms Glatiramer acetate
MFCD04113403
UNII-5M691HL4BO
Copolymer 1
Copaxone
COP-1
Description Glatiramer acetate, a synthetic analogue of myelin basic protein and an immunomodulating agent, can be used for the research of multiple sclerosis. Glatiramer acetate exhibits strong and promiscuous binding to MHC molecules and consequent competition with various myelin antigens for their presentation to T cells. A further aspect of its action is potent induction of specific suppressor cells of the T helper 2 (Th2) type that migrate to the brain and lead to in situ bystander suppression[1][2][3].
Related Catalog
In Vitro Glatiramer acetate (25-100 mg/kg; S.c; 5 days) increase BDNF levels[3]. In huntington’s disease (HD) mouse model, the N171-82Q transgenic mouse line, which exhibits a more rapidly progressing disease course. Glatiramer acetate (1 mg/mouse; s.c.; 5×week) beginning at 8 weeks of age and continuing until 20 weeks of age, which is near the age of death due to the disease. Glatiramer acetate elicited improves performance on several motor function measures. Glatiramer acetate significantly improves the performance of N171-82Q transgenic mice at 15 weeks of age in the rotarod test measured over the course of 4 days[3].
References

[1]. McKeage K. Glatiramer Acetate 40 mg/mL in Relapsing-Remitting Multiple Sclerosis: A Review. CNS Drugs. 2015;29(5):425-432.

[2]. Arnon R, et al. Mechanism of action of glatiramer acetate in multiple sclerosis and its potential for the development of new applications. Proc Natl Acad Sci U S A. 2004;101 Suppl 2(Suppl 2):14593-14598.

[3]. Corey-Bloom J, et al. Beneficial effects of glatiramer acetate in Huntington's disease mouse models: Evidence for BDNF-elevating and immunomodulatory mechanisms. Brain Res. 2017;1673:102-110.

[4]. Aharoni R, et al. Glatiramer acetate-specific T cells in the brain express T helper 2/3 cytokines and brain-derived neurotrophic factor in situ [published correction appears in Proc Natl Acad Sci U S A. 2005 Aug 23;102(34):12288]. Proc Natl Acad Sci U S A. 2003;100(24):14157-14162.

Boiling Point 385.2ºC at 760mmHg
Melting Point >239°C (dec.) (lit.)
Molecular Formula (C9H11NO3.C6H14N2O2.C5H9NO4.C3H7NO2)x.xC2H4O2
Molecular Weight 623.65000
Flash Point 186.7ºC
Exact Mass 623.30100
PSA 374.13000
LogP 2.14760
Vapour Pressure 1.27E-06mmHg at 25°C
Storage condition 2-8°C